Abstract
Background: Metadichol® (nano policosanol) is a novel nanoemulsion of long-chain alcohols derived from natural food sources that has demonstrated broad immunomodulatory properties via inverse agonism of the vitamin D receptor (VDR). Its ability to modulate gene expression across diverse cancer cell lines presents a unique opportunity to explore its anticancer mechanisms through cytokine and transcription factor regulation.
Objective: This study investigated the effect of Metadichol at five concentrations (0.1 pg/mL to 100 ng/mL) on the expression of interleukin-15 (IL-15), T-box transcription factor 21 (TBET/TBX21), and Eomesodermin (EOMES) in six human cancer cell lines representing distinct tumor types: A549 (lung adenocarcinoma), FaDu (pharyngeal squamous cell carcinoma), HCT116 (colorectal carcinoma), HeLa (cervical adenocarcinoma), HepG2 (hepatocellular carcinoma), and U87MG (glioblastoma multiforme).
Methods: Quantitative gene expression analysis was performed on all six cell lines treated with Metadichol across the five concentrations described above. Fold-change values were normalized to untreated controls, and IL-15, TBET, and EOMES expression were quantified to assess dose-response relationships.
Results: IL-15 expression was consistently and significantly upregulated across all six cancer cell lines following Metadichol treatment. The most pronounced induction was observed in HCT116 cells at 1 pg/mL (4.30-fold), followed by HepG2 at 1 pg/mL (3.66-fold), HeLa at 1 ng/mL (3.04-fold), FaDu at 1 pg/mL (2.81-fold), U87MG at 1 ng/mL (2.69-fold), and A549 at 1 pg/mL (2.45-fold). TBET and EOMES exhibited variable, cell line-dependent expression patterns, with selective upregulation in certain contexts. The ultra-low effective concentrations (picogram range) are consistent with Metadichol's known mechanisms of action.
Conclusions: Metadichol potently and consistently induces IL-15 expression across multiple cancer cell types. Given IL-15's central role in activating natural killer (NK) cells, cytotoxic CD8+ T cells, memory T cells, and B cells, this finding positions Metadichol as a promising immunomodulatory compound capable of reactivating innate and adaptive antitumor immunity. The concurrent modulation of TBET and EOMES, key transcription factors governing effector lymphocyte differentiation, further supports a broad immunostimulatory mechanism. These results warrant further preclinical and clinical investigation of Metadichol as an adjunct cancer immunotherapy.